Should amylin have been obesity therapeutics’ primary target from the start?
As Novo’s amylin/GLP-1 combo CagriSema nears possible FDA approval and amylin-targeting assets from Eli Lilly and Zealand Pharma yield late-stage…
As Novo’s amylin/GLP-1 combo CagriSema nears possible FDA approval and amylin-targeting assets from Eli Lilly and Zealand Pharma yield late-stage…